BR112018010690A8 - vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos - Google Patents

vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos Download PDF

Info

Publication number
BR112018010690A8
BR112018010690A8 BR112018010690A BR112018010690A BR112018010690A8 BR 112018010690 A8 BR112018010690 A8 BR 112018010690A8 BR 112018010690 A BR112018010690 A BR 112018010690A BR 112018010690 A BR112018010690 A BR 112018010690A BR 112018010690 A8 BR112018010690 A8 BR 112018010690A8
Authority
BR
Brazil
Prior art keywords
dengue
virus
antigens
bank
vaccine containing
Prior art date
Application number
BR112018010690A
Other languages
English (en)
Other versions
BR112018010690A2 (pt
Inventor
Fukuda Aki
Komura Fusae
Kameyama Kazuhisa
Sonoda Kengo
Yoshimura Masaya
Abe Motoharu
Uchida Naomi
Maruno Shinichi
Takagi Shota
Yamaori Susumu
Shinmura Yasuhiko
Hayashi Yasuhisa
Original Assignee
The Chemo Sero Therapeutic Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute filed Critical The Chemo Sero Therapeutic Res Institute
Publication of BR112018010690A2 publication Critical patent/BR112018010690A2/pt
Publication of BR112018010690A8 publication Critical patent/BR112018010690A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a uma vacina altamente segura da dengue a qual se descobriu que induziu uma resposta de anticorpos neutralizantes contra todos os quatro sorotipos do vírus da dengue sem desenvolver mais do que um nível fixo de viremia com uma única administração. a presente invenção se refere a proporcionar uma formulação de vírus da dengue tetravalente que é excelente tanto em eficácia (resposta de anticorpos neutralizantes) quanto em segurança (viremia).
BR112018010690A 2015-11-27 2016-11-25 vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos BR112018010690A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-232013 2015-11-27
JP2015232013 2015-11-27
PCT/JP2016/085077 WO2017090762A1 (ja) 2015-11-27 2016-11-25 デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン

Publications (2)

Publication Number Publication Date
BR112018010690A2 BR112018010690A2 (pt) 2018-11-13
BR112018010690A8 true BR112018010690A8 (pt) 2019-02-26

Family

ID=58763255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010690A BR112018010690A8 (pt) 2015-11-27 2016-11-25 vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos

Country Status (15)

Country Link
US (1) US10655110B2 (pt)
EP (1) EP3382012A4 (pt)
JP (2) JP6910956B2 (pt)
KR (2) KR102297300B1 (pt)
CN (1) CN108699534B (pt)
AU (1) AU2016360487C1 (pt)
BR (1) BR112018010690A8 (pt)
CA (1) CA3005814C (pt)
IL (1) IL259451B (pt)
MX (1) MX2018006500A (pt)
MY (1) MY194650A (pt)
PH (1) PH12018501107A1 (pt)
SG (2) SG11201804317YA (pt)
TW (1) TWI736563B (pt)
WO (1) WO2017090762A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
EP3000477A1 (en) * 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
PT1159968E (pt) 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
WO2006134443A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
KR101536612B1 (ko) 2005-06-17 2015-07-14 사노피 파스퇴르 약독화된 뎅기 혈청형 1 균주
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2012051461A2 (en) * 2010-10-13 2012-04-19 Primordial Soup, Llc Screw captivator
MY168959A (en) * 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
SG10201702292YA (en) * 2012-09-21 2017-05-30 Agency Science Tech & Res Novel attenuated dengue virus strains for vaccine application
PL3539565T3 (pl) * 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach

Also Published As

Publication number Publication date
SG11201804317YA (en) 2018-06-28
JP2021168672A (ja) 2021-10-28
TW201726913A (zh) 2017-08-01
AU2016360487C1 (en) 2021-07-22
US10655110B2 (en) 2020-05-19
TWI736563B (zh) 2021-08-21
NZ742683A (en) 2021-08-27
JP7232289B2 (ja) 2023-03-02
CN108699534A (zh) 2018-10-23
MY194650A (en) 2022-12-09
EP3382012A1 (en) 2018-10-03
KR102297300B1 (ko) 2021-09-02
CN108699534B (zh) 2022-05-24
IL259451B (en) 2022-01-01
PH12018501107A1 (en) 2019-01-21
EP3382012A4 (en) 2019-07-03
CA3005814A1 (en) 2017-06-01
JPWO2017090762A1 (ja) 2018-09-20
SG10201913338XA (en) 2020-02-27
KR102373570B1 (ko) 2022-03-10
BR112018010690A2 (pt) 2018-11-13
US20180340155A1 (en) 2018-11-29
WO2017090762A1 (ja) 2017-06-01
AU2016360487B2 (en) 2021-01-21
IL259451A (en) 2018-07-31
KR20210083384A (ko) 2021-07-06
MX2018006500A (es) 2019-02-26
AU2016360487A1 (en) 2018-07-12
JP6910956B2 (ja) 2021-07-28
CA3005814C (en) 2022-09-27
AU2016360487A2 (en) 2018-07-26
KR20180080331A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
BR112014024612A2 (pt) ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX2017015462A (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
BR112016026651A2 (pt) evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina
BR112017009510A2 (pt) composições compreendendo ciclosporina
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
MY177587A (en) Multivalent vlp conjugates
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
EA201791525A2 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112018010690A8 (pt) vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
MX368601B (es) Composicion inmunogenica contra la aeromonas hydrophila.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: KM BIOLOGICS CO., LTD. (JP)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]